Stem, Inc.

Сильный индекс, без изменений. Быки крепко уверены в своих позициях.

Strong index, flat. The bulls are very confident in their positions.

Сильный индекс, незначительно упал. Рынок не поддерживает быков.

Strong index, slightly down. The market does not support the bulls.

Сильный индекс, значительно упал. Отток средств из лонгов увеличился и находится на высоком уровне.

Strong index, significantly down. The outflow of funds from longs has increased and is at a high level.

DXC Technology Company. (DXC) came out with quarterly earnings of $0.4 per share, missing the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -4.76%. A quarter ago, it was expected that this company would post earnings of $0.74 per share when it actually produced earnings of $0.77, delivering a surprise of +4.05%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
DXC Technology, which belongs to the Zacks Computers - IT Services industry, posted revenues of $3 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.46%. This compares to year-ago revenues of $3.16 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
DXC Technology shares have lost about 19.7% since the beginning of the year versus the S&P 500's gain of 6.9%.
What's Next for DXC Technology?
While DXC Technology has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for DXC Technology was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.73 on $3.04 billion in revenues for the coming quarter and $2.61 on $12.19 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computers - IT Services is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Stem, Inc. (STEM), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 12.
This company is expected to post quarterly loss of $1.76 per share in its upcoming report, which represents a year-over-year change of +52.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Stem, Inc.'s revenues are expected to be $31.6 million, down 17.6% from the year-ago quarter.
Should You Invest in DXC Technology Company. (DXC)?
Before you invest in DXC Technology Company. (DXC), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

DXC Technology Company. (DXC) Lags Q1 Earnings Estimates

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Stem (STEM) Q1 2026 Earnings Transcript

CoStar Group (CSGP) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +27.78%. A quarter ago, it was expected that this commercial real estate information and marketing provider would post earnings of $0.14 per share when it actually produced earnings of $0.17, delivering a surprise of +21.43%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
CoStar, which belongs to the Zacks Computers - IT Services industry, posted revenues of $833.6 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.91%. This compares to year-ago revenues of $692.6 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
CoStar shares have added about 9.1% since the beginning of the year versus the S&P 500's gain of 16.9%.
What's Next for CoStar?
While CoStar has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for CoStar was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.31 on $893.27 million in revenues for the coming quarter and $0.84 on $3.23 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computers - IT Services is currently in the top 18% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Stem, Inc. (STEM), is yet to report results for the quarter ended September 2025. The results are expected to be released on October 29.
This company is expected to post quarterly loss of $1.85 per share in its upcoming report, which represents a year-over-year change of +56%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Stem, Inc.'s revenues are expected to be $41.1 million, up 40.3% from the year-ago quarter.
Should You Invest in CoStar Group, Inc. (CSGP)?
Before you invest in CoStar Group, Inc. (CSGP), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CoStar Group (CSGP) Q3 Earnings and Revenues Top Estimates

In this video, Motley Fool contributor Jason Hall makes the case for Brookfield Renewable (NYSE: BEPC)(NYSE: BEP), Stem Energy (NYSE: STEM), Enphase Energy (NASDAQ: ENPH), and First Solar (NASDAQ: FSLR) as a basket of stocks that could double in value over the next five years.
*Stock prices used were from the afternoon of Oct. 17, 2025. The video was published on Oct. 17, 2025.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Should you invest $1,000 in Enphase Energy right now?
Before you buy stock in Enphase Energy, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Enphase Energy wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $646,805!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,113!*
Now, it’s worth noting Stock Advisor’s total average return is 1,055% — a market-crushing outperformance compared to 188% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 13, 2025
Jason Hall has positions in Brookfield Renewable, Brookfield Renewable Partners, Enphase Energy, First Solar, and Stem and has the following options: short January 2026 $1 puts on Stem and short January 2027 $40 puts on Enphase Energy. The Motley Fool has positions in and recommends First Solar. The Motley Fool recommends Brookfield Renewable, Brookfield Renewable Partners, Enphase Energy, and Stem. The Motley Fool has a disclosure policy. Jason Hall is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Got $10,000? 4 Top AI Grid Resilience Stocks to Buy That Could Double by 2030

Stem STEM shares have gained 11.9% since it reported second-quarter 2025 results on Aug. 7. The uptick can be attributed to strong growth in software and managed services, new customer engagements, expanded professional services, and increased recurring revenue momentum.
In the second quarter of 2025, Stem reported a loss of $3.73 per share, which was narrower than $4.40 per share reported in the year-ago quarter. The figure missed the Zacks Consensus Estimate by 24.33%.
Revenues of $38.4 million climbed 12.9% year over year and beat the consensus mark by 15.93%.
Stem shares have gained 15.5% year to date, outperforming the Zacks Computer & Technology sector’s 13.5% return.
Stem, Inc. Price, Consensus and EPS Surprise
STEM Q2 Top-Line Details
Solar Software revenues (24.8% of revenues) climbed 20.4% year over year to $9.5 million. Edge Hardware (31.5% of revenues) increased 8.6% year over year to $12.1 million.
Project and Professional Services (6.1% of revenues) increased 76.1% year over year to $2.3 million. Storage Software & Managed services (23.5% of revenues) increased 53.2% year over year to $9 million. Battery Hardware resale (14.2% of revenues) decreased 30% year over year to $5.4 million.
In the second quarter of 2025, Stem maintained bookings of $34.3 million, slightly down from $34.5 million in the first quarter of 2025, and increased its contracted backlog by 6% to $26.8 million.
Storage operating assets under management (AUM) grew 42% year over year to 1.7 gigawatt hours (GWh), while solar operating AUM increased 22% year over year to 32.7 gigawatts (GW).
Contracted Annual Recurring Revenue remained nearly flat at $69.2 million, while Annual Recurring Revenue (ARR) rose 3% quarter over quarter to $58.5 million, reflecting 22% year-over-year growth.
STEM Q2 Operating Details
STEM’s second-quarter 2025 non-GAAP gross margin expanded 900 basis points (bps) to 48.9%.
In the second quarter, operating expenses decreased 95.6% year over year to $26.1 million. In the reported quarter, research & development expenses declined 34.6% year over year to $10 million. General & administrative expenses decreased 43.8% year over year to $8.9 million. Selling and marketing expenses decreased 33.8% year over year to $7.3 million.
In the second quarter of 2025, adjusted EBITDA reached $3.8 million, up from an adjusted EBITDA loss of 11.3 million in the second quarter of 2024.
STEM Balance Sheet Details
As of June 30, 2025, Stem had cash and cash equivalents of $40.8 million compared with $58.6 million as of March 31, 2025.
Operating cash outflow for the second quarter of 2025 was $21.3 million compared with $11.9 million in the second quarter of 2024.
STEM Provides 2025 Guidance
Stem now expects 2025 revenues between $125 million and $175 million.
Software, edge hardware, & services are expected to be between $120 million and $140 million.
For 2025, Battery hardware resale is expected to be approximately $35 million.
Non-GAAP gross margin is expected to be between 30% and 40%.
Adjusted EBITDA is expected to be between a loss of $10 million and a gain of $5 million.
Year-end ARR is projected to be between $55 million and $65 million.
Zacks Rank & Stocks to Consider
Stem currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Computer and Technology sector are Autodesk ADSK, Applied Materials AMAT, and Cisco Systems CSCO. Each stock carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Autodesk is set to report second-quarter fiscal 2026 results on Aug. 28. Autodesk shares have lost 3.7% year to date.
Applied Materials is slated to report third-quarter fiscal 2025 results on Aug. 14. Applied Materials shares have gained 13.5% year to date.
Cisco Systems is set to report fourth-quarter fiscal 2025 results on Aug. 13. Cisco Systems shares ave rallied 19.3% year to date.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

STEM Shares Gains 12% on Narrower Q2 Loss, Revenues Increased Y/Y

In trading on Friday, rental, leasing, & royalty shares were relative leaders, up on the day by about 1.2%. Leading the group were shares of VirnetX Holding, up about 7.3% and shares of VOC Energy Trust up about 4.6% on the day.
Also showing relative strength are electronic equipment & products shares, up on the day by about 1.1% as a group, led by Stem, trading up by about 49.4% and Westwater Resources, trading up by about 27.4% on Friday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Friday Sector Leaders: Rental, Leasing, & Royalty, Electronic Equipment & Products

Stem, Inc. STEM shares ended the last trading session 8.8% higher at $6.71. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 33.7% loss over the past four weeks.
STEM is benefiting from its focus on high-margin software and services, particularly PowerTrack and managed services, along with cost reductions and improved operational efficiency.
This company is expected to post quarterly loss of $3.00 per share in its upcoming report, which represents a year-over-year change of +31.8%. Revenues are expected to be $33.1 million, down 2.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Stem, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on STEM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Stem is part of the Zacks Computers - IT Services industry. Cognizant CTSH, another stock in the same industry, closed the last trading session 0.8% higher at $77.59. CTSH has returned -4.3% in the past month.
Cognizant's consensus EPS estimate for the upcoming report has changed +0.7% over the past month to $1.26. Compared to the company's year-ago EPS, this represents a change of +7.7%. Cognizant currently boasts a Zacks Rank of #2 (Buy).
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stem (STEM) Soars 8.8%: Is Further Upside Left in the Stock?

Teladoc (TDOC) shares rallied 14.4% in the last trading session to close at $7.89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.3% gain over the past four weeks.
Teladoc witnessed a price rise after Citron Research highlighted strong growth prospects following the company’s Goldman Sachs presentation, where management revealed that embedding BetterHelp in employer health plans could drastically improve conversion rates. The recent acquisition of UpLift enables insurance billing. Citron also emphasized TDOC’s AI edge and scale as key drivers of future profitability.
Besides, Teladoc's competitive strengths lie in its unmatched integration of virtual care services, global reach and data-driven innovation. It offers a comprehensive suite of clinical services—from wellness and acute care to chronic and mental health management—through a highly scalable, secure and API-driven platform. Its proprietary engagement science, predictive analytics and personalized communications drive exceptional member utilization.
This telehealth services provider is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +7.1%. Revenues are expected to be $621.69 million, down 3.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Teladoc, the consensus EPS estimate for the quarter has been revised 3.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TDOC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Teladoc is a member of the Zacks Medical Services industry. One other stock in the same industry, LifeMD, Inc. (LFMD), finished the last trading session 3.1% lower at $14.3. LFMD has returned 28% over the past month.
For LifeMD, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. This represents a change of +89.5% from what the company reported a year ago. LifeMD currently has a Zacks Rank of #3 (Hold).
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?

Exelixis (EXEL) shares soared 7.4% in the last trading session to close at $43.37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.8% loss over the past four weeks.
Shares rallied following the company's announcement that the late-stage STELLAR-303 study met one of its two dual primary endpoints, demonstrating a statistically significant improvement in overall survival (OS) for the intent-to-treat (ITT) population when treated with zanzalintinib in combination with Tecentriq compared to the current standard-of-care drug, regorafenib.
The positive data from this study increases the likelihood of a potential approval of zanzalintinib.
This drug developer is expected to post quarterly earnings of $0.63 per share in its upcoming report, which represents a year-over-year change of -25%. Revenues are expected to be $571.08 million, down 10.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Exelixis, the consensus EPS estimate for the quarter has been revised 0.8% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on EXEL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Exelixis is part of the Zacks Medical - Biomedical and Genetics industry. Cartesian Therapeutics, Inc. (RNAC), another stock in the same industry, closed the last trading session 0.7% higher at $9.83. RNAC has returned 6.6% in the past month.
Cartesian Therapeutics, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.77. Compared to the company's year-ago EPS, this represents a change of -242.6%. Cartesian Therapeutics, Inc. currently boasts a Zacks Rank of #3 (Hold).
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?

Nektar Therapeutics (NKTR) shares soared 12.1% in the last trading session to close at $9.54. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 13.2% loss over the past four weeks.
The stock rallied as investor optimism grew over the company's review of top-line data from the phase IIb REZOLVE-AD study evaluating its pipeline candidate, rezpegaldesleukin, for treating moderate-to-severe atopic dermatitis.
This biopharmaceutical company is expected to post quarterly loss of $2.53 per share in its upcoming report, which represents a year-over-year change of +32.5%. Revenues are expected to be $10.78 million, down 54.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Nektar, the consensus EPS estimate for the quarter has been revised 10.5% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on NKTR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Nektar belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Indivior PLC (INDV), closed the last trading session 0.4% lower at $13.95. Over the past month, INDV has returned 24.4%.
For Indivior, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.25. This represents a change of -43.2% from what the company reported a year ago. Indivior currently has a Zacks Rank of #3 (Hold).
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stem, Inc.

Price history and volume

360 Overview

Investment risk — high

Investment potential — low

Bearish sentiment among traders

About